ArticleARYA atherosclerosis2024
Evaluation of RehaCom cognitive rehabilitation on different aspects of visual attention in patients with middle cerebral artery ischemia: A nonblinded randomized clinical trial.
Article in ARYA atherosclerosis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCerebral ischemia or stroke is the second leading cause of death in the world, and most surviving patients suffer from long-term physical and cognitive disabilities, which create many social and economic problems for them and society. Visual attention impairment is a common cognitive complication among patients with cerebral ischemia, especially in the Middle Cerebral Artery (MCA). One way to improve attention in these patients is cognitive rehabilitation. RehaCom software is one of the computer-based tools to rehabilitate visual attention in these patients. The purpose of this study was to evaluate RehaCom cognitive rehabilitation on different aspects of visual attention in patients with middle cerebral artery ischemia.
methodsIn this single-blind randomized clinical trial, 30 patients with cerebral ischemia in MCA territories were selected and randomly divided into control (n=15) and intervention (n=15) groups. Visual attention of both groups was assessed before the treatments using the Integrated Visual-Auditory test (IVA). Then the intervention group was rehabilitated for 8 sessions of 45 minutes each with RehaCom cognitive software, according to our selected modules, while the control group was only under intervention by non-targeted computer games. After applying the treatments, visual attention in the two groups was assessed using the IVA test.
resultsThere were no significant differences in visual focus attention between the intervention and control groups before the intervention (29.20±30.06 and 49.53±29.69, P value >0.05). In addition, there were no significant differences in visual selective attention in both groups before the study (23.07±24.73, 39.27±27.08, P value >0.05). However, significant differences were found in visual sustained attention, visual alternating attention, and visual divided attention at baseline (P value <0.05). After the intervention, visual focus attention in the intervention group was significantly higher than in the control group (84.67±26.51, 57.20±31.44, P value <0.05). RehaCom cognitive software intervention increased visual divided attention in the intervention group (88.40±14.85 versus 72.70±25.73, P value <0.05).
conclusionThese results demonstrate that using RehaCom cognitive software can improve focus attention and visual attention in the intervention group. Cognitive rehabilitation with RehaCom was able to improve visual attention deficits in patients with middle cerebral artery ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.